✦ LIBER ✦

A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer

✍ Scribed by R. Rosell; J. Carles; I. Moreno; N. Ribelles; V. Solano; A. Barnadas; A. Abad; A. Ariza; I. Pellicer

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 660 KB
Volume: 67
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910515)67:10<2448::aid-cncr2820671009>3.0.co;2-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of recombinant beta inter

Phase II study of recombinant beta interferon in patients with advanced non-small-cell lung carcinoma

✍ Ettinger, David S. ;Harwood, Kerry 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

Eighteen patients with advanced non-smallcell lung cancer (NSCLC) received recombinant beta interferon, 90 million units three times weekly. No complete or partial responses were seen. Five patients had stable disease for several months. Most patients experienced some toxicity, most commonly fever a

A phase I trial of ifosfamide, mesna, an

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer a cancer and leukemia group B study

✍ Stephen L. Graziano; James E. Herndon II; Frederick Richards II; Santo Difino; C 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 737 KB

Combination of chemotherapy and recombin

Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer: Multicentric randomized FONICAP trial report

✍ Andrea Ardizzoni; Franco Salvati; Riccardo Rosso; Paolo Bruzzi; Alessandra Rubag 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Background. Preclinical data suggested that alphainterferon (IFN) may potentiate chemotherapy cytotoxicity. Methods. A prospective multicentric randomized trial was initiated to assess the clinical benefit of adding This work was conducted by the Italian Lung Cancer Task Force (FONICAP), which carr

Phase ii evaluation of a combination of

Phase ii evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer

✍ Alex Yuang-Chi Chang; J. Philip Kuebler; Douglass C. Tormey; Susan Anderson; Kis 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 606 KB

A phase II study of recombinant human al

A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer

✍ Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: A cancer and leukemia group B study

✍ Graziano, Stephen L. ;Lee, Kewchang ;Propert, Kathleen J. ;Tinsley, Roger ;Hayes 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB 👁 1 views

## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty‐five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin